SCHEMBL6901625

SCHEMBL6901625

CC(C)c1ccc(CC(=O)N[C@H](C)c2ncc(Br)s2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 4/20 0.50
CACNA1I Q9P0X4 4/20 0.50
CNR2 P34972 3/20 0.50
CACNA1G O43497 3/20 0.50
KCNH2 Q12809 1/20 0.50
ALDH1A1 P00352 4/20 0.48
HTT P42858 1/20 0.48
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
CDK5 Q00535 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
KDM4E B2RXH2 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.40
KEAP1 Q14145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064504 0.77 CACNA1I (0.65) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL1066005 0.72 CACNA1I (0.67) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL3042543 0.72 CACNA1I (0.60) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL3037471 0.72 CACNA1H (0.60) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL17451429 0.72 CACNA1I (0.67) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL3030405 0.72 CACNA1H (0.60) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL6901966 0.72 ALDH1A1 (0.61) ALDH1A1CCNE1CDK2CDK5SMN1; SMN2
SCHEMBL23553286 0.72 CNR2 (0.66) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL1062854 0.71 CACNA1I (0.75) CACNA1HCACNA1ICNR2CACNA1GKCNH2
SCHEMBL13557883 0.70 CNR2 (0.58) CACNA1HCACNA1ICNR2CACNA1GALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493297-B1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME (US) 2016-08-17 EP disclosed
EP-2493297-B1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME (US) 2016-08-17 EP disclosed
US-8987310-B2 Heterocycle amide T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8987310-B2 Heterocycle amide T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-20120202852-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME LLC 2012-08-09 US disclosed
US-20120202852-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME LLC 2012-08-09 US disclosed
WO-2011053542-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202852-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS CACNA1G, CACNA1H, CACNA1I CACNA1H 2/4885CACNA1I 3/4885CNR2 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.